Loading
A phase 3 trial testing SCTC21C in multiple myeloma, now recruiting.
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant is a phase 3 interventional study registered as NCT07297329, led by Sinocelltech, and recruiting on the registry. Official title: A Phase 3 Randomised, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant. Planned enrolment is 292 participants (estimated). The study started in 2025-12-29 and primary completion is expected in 2027-12. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/